Strategies to Overcome HLA Sensitization and Improve Access to Retransplantation after Kidney Graft Loss

An increasing number of patients waitlisted for kidney transplantation have a previously failed graft. Retransplantation provides a significant improvement in morbidity, mortality, and quality of life when compared to dialysis. However, HLA sensitization is a major barrier to kidney retransplantation and the majority of the highly sensitized patients are waiting for a subsequent kidney transplant. A multidisciplinary team that includes immunogeneticists, transplant nephrologists and surgeons, and adequate allocation policies is fundamental to increase access to a kidney retransplant. A review of Pubmed, ScienceDirect, and the Cochrane Library was performed on the challenges of kidney retransplantation after graft loss, focusing on the HLA barrier and new strategies to overcome sensitization. Conclusion: Technical advances in immunogenetics, new desensitization protocols, and complex allocation programs have emerged in recent years to provide a new hope to kidney recipients with a previously failed graft.

[1]  F. Claas,et al.  European Guideline for the Management of Kidney Transplant Patients With HLA Antibodies: By the European Society for Organ Transplantation Working Group , 2022, Transplant International.

[2]  C. Couchoud,et al.  Association between kidney retransplantation and survival according to age in the French national cohort of dialysis patients , 2022, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  H. Sá,et al.  Kidney Retransplant: Not Too Old for a Second Chance. , 2022, Transplantation proceedings.

[4]  Christine A. White,et al.  Immunosuppressant Medication Use in Patients with Kidney Allograft Failure: A Prospective Multicenter Canadian Cohort Study , 2022, Journal of the American Society of Nephrology : JASN.

[5]  A. Israni,et al.  OPTN/SRTR 2020 Annual Data Report: Kidney , 2022, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  B. Kiberd,et al.  Disparities in Access to Preemptive Repeat Kidney Transplant: Still Missing the Mark? , 2021, Kidney360.

[7]  D. Abramowicz,et al.  Waiting Time for Second Kidney Transplantation and Mortality , 2021, Clinical journal of the American Society of Nephrology : CJASN.

[8]  L. Cantwell,et al.  Prolonged immunosuppression does not improve risk of sensitization or likelihood of retransplantation after kidney transplant graft failure , 2021, Transplant international : official journal of the European Society for Organ Transplantation.

[9]  P. Nickerson,et al.  Significance of HLA-DQ in kidney transplantation - Time to re-evaluate HLA matching priorities to improve transplant outcomes? An expert review and recommendations. , 2021, Kidney international.

[10]  F. Claas,et al.  Highly Sensitized Patients Are Well Served by Receiving a Compatible Organ Offer Based on Acceptable Mismatches , 2021, Frontiers in Immunology.

[11]  J. Friedewald,et al.  The failing kidney allograft: A review and recommendations for the care and management of a complex group of patients , 2021, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  S. Knechtle,et al.  Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization , 2021, Frontiers in Immunology.

[13]  D. Segev,et al.  Evolving Trends in Risk Profiles and Outcomes in Older Adults Undergoing Kidney Retransplantation , 2021, Transplantation.

[14]  J. Schold,et al.  Association Between Donor-Recipient Biological Relationship and Allograft Outcomes After Living Donor Kidney Transplant , 2021, JAMA network open.

[15]  M. Crespo,et al.  Stratifying the humoral risk of candidates to a solid organ transplantation: a proposal of the ENGAGE working group , 2021, Transplant international : official journal of the European Society for Organ Transplantation.

[16]  J. Friedewald,et al.  Kidney recipients with allograft failure, transition of kidney care (KRAFT): A survey of contemporary practices of transplant providers , 2021, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[17]  L. Lobato,et al.  Eplet-based virtual PRA increases transplant probability in highly-sensitized patients. , 2021, Transplant immunology.

[18]  S. Fuggle,et al.  A Europe wide acceptable mismatch program will enable transplantation of long waiting highly sensitised patients with a compatible donor. , 2020, Transplant immunology.

[19]  B. Lonze A review of imlifidase in solid organ transplantation , 2020, Expert opinion on biological therapy.

[20]  C. Thongprayoon,et al.  Outcomes of kidney retransplantation in recipients with prior posttransplant lymphoproliferative disorders: An analysis of the 2000–2019 UNOS/OPTN database , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  R. Montgomery,et al.  Imlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes) , 2020, Transplantation.

[22]  V. Kher,et al.  Paired kidney exchange transplantation – pushing the boundaries , 2020, Transplant international : official journal of the European Society for Organ Transplantation.

[23]  A. Courtney,et al.  Living Donor Kidney Transplantation Improves Graft and Recipient Survival in Patients with Multiple Kidney Transplants , 2020, Journal of clinical medicine.

[24]  C. Ahn,et al.  Weaning Immunosuppressant in Patients with Failing Kidney Grafts and The Outcomes: A Single-Center Retrospective Cohort Study , 2020, Scientific Reports.

[25]  Rachel J. Johnson,et al.  Overview of the Evolution of the UK Kidney Allocation Schemes , 2020, Current Transplantation Reports.

[26]  D. Roelen,et al.  Donor-specific B Cell Memory in Alloimmunized Kidney Transplant Recipients: First Clinical Application of a Novel Method , 2020, Transplantation.

[27]  C. Thongprayoon,et al.  Outcomes of kidney retransplantation after graft loss as a result of BK virus nephropathy in the era of newer immunosuppressant agents , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[28]  J. Gill,et al.  Access to Kidney Transplantation after a Failed First Kidney Transplant and Associations with Patient and Allograft Survival: An Analysis of National Data to Inform Allocation Policy. , 2019, Clinical journal of the American Society of Nephrology : CJASN.

[29]  R. Redfield,et al.  Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti‐CD20 monoclonal antibody for the desensitization of candidates for renal transplant , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[30]  M. Bots,et al.  Allocation to highly sensitized patients based on acceptable mismatches results in low rejection rates comparable to nonsensitized patients , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[31]  J. Hodson,et al.  Outcomes in Third and Fourth Kidney Transplants Based on the Type of Donor. , 2019, Transplantation.

[32]  M. Metzger,et al.  Epitope load identifies kidney transplant recipients at risk of allosensitization following minimization of immunosuppression. , 2019, Kidney international.

[33]  G. Lucisano,et al.  Allosensitization after transplant failure: the role of graft nephrectomy and immunosuppression – a retrospective study , 2019, Transplant international : official journal of the European Society for Organ Transplantation.

[34]  Douglas E Schaubel,et al.  US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States. , 2019, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[35]  M. Naesens,et al.  Indications, risks and impact of failed allograft nephrectomy. , 2019, Transplantation reviews.

[36]  L. Henderson,et al.  The Impact of Withdrawal of Maintenance Immunosuppression and Graft Nephrectomy on HLA Sensitization and Calculated Chance of Future Transplant , 2018, Transplantation direct.

[37]  A. Waterman,et al.  The first 9 years of kidney paired donation through the National Kidney Registry: Characteristics of donors and recipients compared with National Live Donor Transplant Registries , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[38]  F. Claas,et al.  How the definition of acceptable antigens and epitope analysis can facilitate transplantation of highly sensitized patients with excellent long-term graft survival , 2018, Current opinion in organ transplantation.

[39]  P. Nickerson,et al.  A Comparison of HLA Molecular Mismatch Methods to Determine HLA Immunogenicity , 2018, Transplantation.

[40]  N. Kamar,et al.  Preemptive second kidney transplantation is associated with better graft survival compared with non‐preemptive second transplantation: a multicenter French 2000–2014 cohort study , 2018, Transplant international : official journal of the European Society for Organ Transplantation.

[41]  J. Malheiro,et al.  Clinical implications of anti-HLA antibodies testing in kidney transplantation , 2018 .

[42]  S. Jordan,et al.  IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. , 2017, The New England journal of medicine.

[43]  R. Bray,et al.  Understanding solid-phase HLA antibody assays and the value of MFI. , 2017, Human immunology.

[44]  A. Cabrita,et al.  Increase of allosensitization after a kidney graft failure: Predictors and effect on retransplantation outcomes. , 2017, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

[45]  Byron H. Smith,et al.  32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody , 2017, Transplantation.

[46]  Rachel J. Johnson,et al.  Post-listing survival for highly sensitised patients on the UK kidney transplant waiting list: a matched cohort analysis , 2017, The Lancet.

[47]  M. Salifu,et al.  Mortality after Renal Allograft Failure and Return to Dialysis , 2017, American Journal of Nephrology.

[48]  R. Redfield,et al.  The mode of sensitization and its influence on allograft outcomes in highly sensitized kidney transplant recipients. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[49]  S. Chadban,et al.  Waiting Time Between Failure of First Graft and Second Kidney Transplant and Graft and Patient Survival , 2016, Transplantation.

[50]  J. Slaven,et al.  Re‐transplants compared to primary kidney transplants recipients: a mate kidney paired analysis of the OPTN/UNOS database , 2016, Clinical transplantation.

[51]  M. Stegall,et al.  Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors. , 2016, The New England journal of medicine.

[52]  B. Chung,et al.  Clinical Significance of HLA-DQ Antibodies in the Development of Chronic Antibody-Mediated Rejection and Allograft Failure in Kidney Transplant Recipients , 2016, Medicine.

[53]  John Gill,et al.  Re-Examining Risk of Repeated HLA Mismatch in Kidney Transplantation. , 2016, Journal of the American Society of Nephrology : JASN.

[54]  C. Ahn,et al.  Desensitization Using Bortezomib and High-dose Immunoglobulin Increases Rate of Deceased Donor Kidney Transplantation , 2016, Medicine.

[55]  J. Ijzermans,et al.  Improving the outcome of kidney transplantation by ameliorating renal ischemia reperfusion injury: lost in translation? , 2016, Journal of Translational Medicine.

[56]  I. Feurer,et al.  Early and Sustained Reduction in Donor-Specific Antibodies in Desensitized Living Donor Kidney Transplant Recipients: A 3-Year Prospective Study , 2016, Transplantation direct.

[57]  Ashesh P. Shah,et al.  Sensitization trends after renal allograft failure: the role of DQ eplet mismatches in becoming highly sensitized , 2016, Clinical transplantation.

[58]  F. Diekmann,et al.  Pre-Emptive Retransplantation in Patients With Chronic Kidney Graft Failure. , 2015, Transplantation proceedings.

[59]  Wai H Lim,et al.  Kidney paired donation: principles, protocols and programs. , 2015, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[60]  Tongyu Lin,et al.  Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. , 2014, JAMA.

[61]  L. Sharples,et al.  Impact of donor mismatches at individual HLA-A, -B, -C, -DR, and -DQ loci on the development of HLA-specific antibodies in patients listed for repeat renal transplantation. , 2014, Kidney international.

[62]  D. Roelen,et al.  Immunogenetics and immunology of transplantation in Leiden. , 2014, Transplant immunology.

[63]  A. Courtney,et al.  Factors influencing survival after kidney transplant failure , 2014, Transplantation research.

[64]  R. Bray,et al.  HLA Antibody Detection With Solid Phase Assays: Great Expectations or Expectations Too Great? , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[65]  M. Haas,et al.  Benefits of Rituximab Combined With Intravenous Immunoglobulin for Desensitization in Kidney Transplant Recipients , 2014, Transplantation.

[66]  J. Schold,et al.  Risk Factors for Retransplant Kidney Recipients: Relisting and Outcomes From Patients' Primary Transplant , 2014, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[67]  M. Zeier,et al.  Influence of Test Technique on Sensitization Status of Patients on the Kidney Transplant Waiting List , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[68]  A. Stiggelbout,et al.  Difference in quality of life, fatigue and societal participation between living and deceased donor kidney transplant recipients , 2013, Clinical transplantation.

[69]  J. Petrozzino,et al.  Efficacy, Outcomes, and Cost-Effectiveness of Desensitization Using IVIG and Rituximab , 2013, Transplantation.

[70]  J. Gill,et al.  Risks and Benefits of Preemptive Second Kidney Transplantation , 2013, Transplantation.

[71]  J. Perl,et al.  Reduced survival and quality of life following return to dialysis after transplant failure: the Dialysis Outcomes and Practice Patterns Study. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[72]  M. Salvadori,et al.  Renal transplant allocation criteria, desensitization strategies and immunosuppressive therapy in retransplant renal patients. , 2012, Journal of nephrology.

[73]  D. Hricik,et al.  Independent of Nephrectomy, Weaning Immunosuppression Leads to Late Sensitization After Kidney Transplant Failure , 2012, Transplantation.

[74]  L. Rostaing,et al.  Donor-specific antibodies after ceasing immunosuppressive therapy, with or without an allograft nephrectomy. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[75]  P. Terasaki,et al.  Durability of Antibody Removal Following Proteasome Inhibitor-Based Therapy , 2012, Transplantation.

[76]  J. Pober,et al.  Neutralizing IL-6 Reduces Human Arterial Allograft Rejection by Allowing Emergence of CD161+ CD4+ Regulatory T Cells , 2011, The Journal of Immunology.

[77]  M. Stegall,et al.  Terminal Complement Inhibition Decreases Antibody‐Mediated Rejection in Sensitized Renal Transplant Recipients , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[78]  R. Montgomery,et al.  Using donor exchange paradigms with desensitization to enhance transplant rates among highly sensitized patients , 2011, Current opinion in organ transplantation.

[79]  L. Kucirka,et al.  Desensitization in HLA-incompatible kidney recipients and survival. , 2011, The New England journal of medicine.

[80]  T. Kozłowski,et al.  Limitations of rituximab/IVIg desensitization protocol in kidney transplantation; is this better than a tincture of time? , 2011, Annals of transplantation.

[81]  A. Lu,et al.  Desensitization protocols and their outcome. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[82]  E. Thervet,et al.  Combined Posttransplant Prophylactic IVIg/Anti-CD 20/Plasmapheresis in Kidney Recipients With Preformed Donor-Specific Antibodies: A Pilot Study , 2010, Transplantation.

[83]  S. Jordan,et al.  Use of Intravenous Immune Globulin and Rituximab for Desensitization of Highly HLA-Sensitized Patients Awaiting Kidney Transplantation , 2010, Transplantation.

[84]  A. Zachary,et al.  Immunogenetics and immunology in transplantation , 2010, Immunologic research.

[85]  S. Jameson,et al.  Diversity in T cell memory: an embarrassment of riches. , 2009, Immunity.

[86]  J. Schold,et al.  A Lifetime Versus a Graft Life Approach Redefines the Importance of HLA Matching in Kidney Transplant Patients , 2009, Transplantation.

[87]  S. Jordan,et al.  Rituximab and intravenous immune globulin for desensitization during renal transplantation. , 2008, The New England journal of medicine.

[88]  D. Schaubel,et al.  Survival on dialysis post-kidney transplant failure: results from the Scientific Registry of Transplant Recipients. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[89]  D. Schaubel,et al.  Evaluating the Survival Benefit of Kidney Retransplantation , 2006, Transplantation.

[90]  M. Stegall,et al.  A Comparison of Plasmapheresis Versus High‐Dose IVIG Desensitization in Renal Allograft Recipients with High Levels of Donor Specific Alloantibody , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[91]  M. Tonelli,et al.  Why Do Preemptive Kidney Transplant Recipients Have an Allograft Survival Advantage? , 2004, Transplantation.

[92]  R. Jofré,et al.  Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. , 2004, Journal of the American Society of Nephrology : JASN.

[93]  I. Doxiadis,et al.  The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. , 2004, Transplantation.

[94]  I. Doxiadis,et al.  THE ACCEPTABLE MISMATCH PROGRAM AS A FAST TOOL TO TRANSPLANT HIGHLY SENSITISED PATIENTS AWAITING A CADAVER KIDNEY: SHORT WAITING TIME AND EXCELLENT GRAFT OUTCOME. , 2004 .

[95]  J. Cambier,et al.  B lymphocyte activation during cognate interactions with CD4+ T lymphocytes: molecular dynamics and immunologic consequences. , 2003, Seminars in immunology.

[96]  J. Soulillou,et al.  Ten-year survival of second kidney transplants: impact of immunologic factors and renal function at 12 months. , 2003, Kidney international.

[97]  Rene J. Duquesnoy,et al.  HLA MATCHMAKER: A MOLECULARLY BASED ALGORITHM FOR HISTOCOMPATIBILITY DETERMINATION , 2003 .

[98]  A. Kausz,et al.  Mortality after kidney transplant failure: the impact of non-immunologic factors. , 2002, Kidney international.

[99]  René J Duquesnoy,et al.  HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. I. Description of the algorithm. , 2002, Human immunology.

[100]  B. Kasiske,et al.  Preemptive kidney transplantation: the advantage and the advantaged. , 2002, Journal of the American Society of Nephrology : JASN.

[101]  R. Zietse,et al.  Immunosuppression should be stopped in patients with renal allograft failure , 2001, Clinical transplantation.

[102]  R. Wolfe,et al.  Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation: multivariate analyses from the United States Renal Data System. , 1998, Transplantation.

[103]  M. Fishbein,et al.  Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. , 1998, Transplantation.

[104]  F. Claas,et al.  Repeated HLA mismatches in cadaveric renal transplantation: is it safe to transplant? , 1997, Transplantation proceedings.

[105]  A. Matas,et al.  Does re-exposure to mismatched HLA antigens decrease renal re-transplant allograft survival? , 1996, Clinical transplantation.

[106]  G. Nyberg,et al.  Renal retransplantation in patients with HLA‐antibodies , 1992 .

[107]  G. Nyberg,et al.  Renal retransplantation in patients with HLA-antibodies. , 1992, Transplant International.